- Blood plasma & plasma derived medicinal products are gaining prominence due to their critical role in treating a wide range of rare and chronic conditions, such as immunodeficiencies, hemophilia, and autoimmune disorders, as well as their expanding use in emergency medicine and critical care
- The increasing prevalence of rare diseases and chronic immune-related disorders, coupled with rising awareness about plasma therapies and advancements in plasma fractionation technologies, is driving the global demand for plasma-derived medicinal products
- North America dominates the blood plasma & plasma derived medicinal products market, holding the largest revenue share of 50.79% in 2025, attributed to rising healthcare expenditures, growing patient population, supportive government regulations, and increasing penetration of international plasma product manufacturers in countries like U.S., Canada, and Mexico
- Asia-Pacific is also projected to be the fastest-growing region in the market during the forecast period, driven by infrastructure development in healthcare, growing access to plasma donation and collection facilities, and strong investments in biotechnology and healthcare R&D
- The immunoglobulins segment is expected to dominate the blood plasma & plasma derived medicinal products market with a market share of 41.63% in 2025, owing to its widespread use in treating immunodeficiency diseases, inflammatory conditions, and neurological disorders, alongside increasing global awareness and regulatory approvals
